Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06303570 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas
A Phase 2 study of Dercum's Disease, sponsored by Caliway Biopharmaceuticals Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06303570: Recruiting Phase 2 study of Dercum's Disease, sponsored by Caliway Biopharmaceuticals Co..
NCT06303570 is a Phase 2 study of Dercum's Disease that is actively recruiting participants, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06303570, a Phase 2 study of Dercum's Disease, is actively recruiting participants, sponsored by Caliway Biopharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas.
Primary Outcome
The Comparative Pain Scale is a 11-point scale (0-10) to assess pain from 0 being "pain free" to 10 being unimaginable/unspeakable pain.
Conditions Studied
Interventions
- DRUG CBL-514 injection
- DRUG 0.9% Sodium chloride
Study Locations (1)
Washington
- Investigator Site - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-11-27 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What NCT06303570 shows while recruiting
NCT06303570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Dercum's Disease appearing as the primary indexed condition, and to 2 interventions - of which CBL-514 injection is the first listed.
NCT06303570 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06303570 about?
NCT06303570 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas". This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas.
What is the current status of trial NCT06303570?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-11-27. Estimated completion is 2026-04.
What conditions does trial NCT06303570 study?
This clinical trial studies the following conditions: Dercum's Disease.
What interventions are being tested in trial NCT06303570?
The interventions under investigation include: CBL-514 injection (DRUG), 0.9% Sodium chloride (DRUG).
Who is sponsoring clinical trial NCT06303570?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06303570 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06303570's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI